Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment


Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy


Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences

GemciTest ®

The first diagnostic to predict the patient response in pancreatic cancer treatment


A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.


A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response


The less toxic and expensive chemotherapy in pancreatic cancer treatment


A combination of biomarkers to identify patients most likely to benefit from gemcitabine

Contest “La Fabrique Aviva”: support and vote for the GemciTest to be part of the regional projects selected on 29.04.2021 in Bordeaux!

Our Expertises

Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.


Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.


Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic and Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.


Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.


A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.

Latest News

ACOBIOM presents the clinical benefit of GemciTesT at ASCO 2021

ACOBIOM presents the clinical benefit of GemciTest® at ASCO 2021

The abstract presented at the 2021 ASCO Annual Conference is a study synthesis of the clinical performance of the CE-IVD molecular test to assess the gemcitabine response in advanced pancreatic cancer.

Read more
Acobiom bénéficie d'un financement européen pour le Gemcitest

Acobiom’s Gemcitest receives a European financial support

Within the framework of the SME Instrument-Phase 1 call for projects, Europe provided a financial support to ACOBIOM in order to evaluate the costs of the current management of pancreatic cancer in France. This study will confirm the sale forecasts of the GemciTest in France and in Europe.

Read more
Financing of ACOBIOM's GemciTest on the WEDOGOOD crowdfunding platform

Crowdfunding for ACOBIOM in 2020

Despite a difficult context in 2020 due to the COVID pandemic, Acobiom managed to raise more than 100,000 euros on the social impact crowdfunding platform WeDoGood.

Read more

Since its foundation, Acobiom has always been at the forefront of Medical Innovation.

Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.

Big Data - Acobiom

Contact us